false
0000820313
0000820313
2026-01-08
2026-01-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 8, 2026
AMPHENOL CORPORATION
(Exact name of registrant as specified in its
charter)
| Delaware |
|
1-10879 |
|
22-2785165 |
(State
or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| 358 Hall Avenue, Wallingford, Connecticut |
|
06492 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (203)
265-8900
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Class A
Common Stock, $0.001 par value |
APH |
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 8, 2026, the Board of Directors of Amphenol Corporation
(the “Company”) voted to increase the number of Directors from eight to nine. Also, on January 8, 2026, to fill the
resulting vacancy, the Board of Directors of the Company appointed Sanjiv Lamba, 61, as a member of the Company’s Board of Directors
effective immediately.
Mr. Lamba will receive cash and equity compensation as a non-employee
director of the Company in accordance with the Company’s non-employee director compensation practices and plans described in the
Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (“SEC”)
on April 4, 2025. Mr. Lamba will receive an interim grant of restricted shares under the 2024 Restricted Stock Plan for Directors of Amphenol
Corporation. This grant will be prorated from the date of his appointment to the Board until the Company’s next annual stockholders
meeting. Mr. Lamba will enter into the Company’s standard form of Indemnification Agreement, which was filed as Exhibit 10.27 to
Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on February 17, 2017.
The Board of Directors has determined that Mr. Lamba is an independent
director under the New York Stock Exchange listing standards. Mr. Lamba has not yet been appointed to serve on any committees of the Board
of Directors. There are no transactions between Mr. Lamba and the Company that would be reportable under Item 404(a) of Regulation
S-K. There is no arrangement or understanding between Mr. Lamba and any other person pursuant to which he was selected as a director.
Item 7.01. Regulation FD Disclosure.
A copy of the Company’s related press release, announcing the
appointment of Mr. Lamba described above, is attached hereto, with this report, as Exhibit 99.1 and incorporated by reference.
The information set forth in this Item 7.01, including the attached
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Document Description |
| |
|
|
| 99.1 |
|
Press Release dated January 8, 2026 |
| 104 |
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
AMPHENOL CORPORATION |
| |
|
|
| |
|
|
| |
By: |
/s/ Lance E. D’Amico |
| |
|
Lance E. D’Amico |
| |
|
Executive Vice President, Secretary and General Counsel |
| |
|
|
| Date: January 8, 2026 |
|
|